Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest update is out from Aptose Biosciences ( (TSE:APS) ).
Aptose Biosciences is advancing tuspetinib (TUS), a promising oral kinase inhibitor, as a frontline therapy for newly diagnosed acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. The TUS+VEN+AZA combination therapy shows potential in overcoming VEN resistance, offering broad efficacy and favorable safety in AML patients, including those with challenging genetic mutations. The ongoing clinical trials aim to establish a new standard of care for AML, targeting significant unmet needs in the market.
See more data about APS stock on TipRanks’ Stock Analysis page.
Trending Articles
- BlackBerry (TSE:BB) Plunges After New MotionWise Schedule Release
- Shareholder Alert for Dentsply Sirona, Inc. (NASDAQ:XRAY)
- Shareholder Alert for Warner Bros. Discovery, Inc. (NASDAQ:WBD)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
